NCT06642844
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06642844
Title Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment (PHARBEVACOL)
Acronym PHARBEVACOL
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors University Hospital, Tours
Indications
Therapies
Age Groups: senior | adult
Covered Countries


No variant requirements are available.